News >

EU Approves Lenalidomide- and Pomalidomide-Based Triplets for Myeloma

Gina Columbus @ginacolumbusonc
Published: Thursday, May 16, 2019

Nadim Ahmed

Nadim Ahmed

The European Commission (EC) has granted an approval to lenalidomide (Revlimid) in combination with bortezomib (Velcade) and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for stem cell transplant, as well as pomalidomide (Pomalyst, US; Imnovid, EU) in combination with bortezomib and dexamethasone (PVd) for the treatment of adult patients with myeloma who have received ≥1 prior treatment regimen that included lenalidomide.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x